All posts by Shenda
-
PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH
9/14/2017
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on September 14, 2017.
-
PDX Pharma welcomes a new Research Assistant, Daniel Bejan.
9/5/2017
PDX Pharma welcomes a new Research Assistant, Daniel Bejan. Daniel’s recently graduated from WSU Vancouver with a Major in Biology and Minors in Chemistry and Molecular Biology (GPA 3.94). He is our top pick among 120 applicants. We are excited to add him to our team.
-
PDX PHARMA WON AN SBIR PHASE I GRANT ($325,000) FROM NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)
8/11/2017
Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I SBIR grant from the National Center for Advancing Translational Sciences to support our pre-clinical research activity during the period of Aug 2017 – Aug 2018. The grant is entitled “Development of topical formulation of […]
-
PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH
6/28/2017
PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.
-
PDX PHARMA WON AN SBIR FAST-TRACK GRANT ($1.7M) FROM NATIONAL CANCER INSTITUTE (NCI)
5/16/2017
Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I/II (Fast-Track) SBIR grant from the National Cancer Institute to support our pre-clinical research activity during the period of May 2017 – May 2020. The grant is entitled “Nanoparticle-based targeted co-delivery of siRNA and taxane […]
-
PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH
3/9/2017
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on March 9, 2017.
-
PRESIDENT HAS SERVED AS A REVIEWER FOR THE FELLOWSHIP: CELL BIOLOGY, DEVELOPMENTAL BIOLOGY, AND BIOENGINEERING [F05] STUDY SECTION FOR THE NIH
3/1/2017
PDX Pharma’s President has served as a reviewer for the Fellowship: Cell Biology, Developmental Biology, and Bioengineering [F05] Study Section for the National Institute of Health (NIH) held on February 28, 2017 – March 1, 2017.
-
DATA ON PDX-001 FOR METASTATIC CANCER PUBLISHED IN MOLECULAR CANCER THERAPEUTICS JOURNAL (IF 5.579)
1/30/2017
PDX Pharmaceuticals has published recent data on PDX-001 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University. PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ and triple-negative breast cancer. The development is in collaboration with OHSU. It has been funded by a fast-track phase I/II SBIR […]
-
DATA ON PDX-001 PUBLISHED IN ONCOTARGET JOURNAL (IF 5.008)
2/15/2016
PDX Pharmaceuticals has published recent data on PDX-001 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University. PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer. The development is in collaboration with OHSU. It has been funded by a fast-track phase I/II SBIR contract from […]
-
President will chair a Nanomedicine/Health Systems section of the 4th SNO Conference
10/27/2015
PDX Pharma’s President will chair a Nanomedicine/Health Systems section of the 4th Sustainable Nanotechnology Organization Conference, to be held on November 8-10th in Portland, OR.
-
President has served as a reviewer for the Gene and Drug Delivery Study Section for the NIH
10/21/2015
PDX Pharma’s President has served as a reviewer for the Gene and Drug Delivery Study Section for the National Institute of Heath (NIH) held in San Francisco from October 21-22th, 2015
-
Data On PDX-002 Published in Biomaterials Journal (IF 8.557)
8/6/2015
PDX Pharmaceuticals has published recent data on PDX-002 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University . PDX-002 is a nanoparticle platform for siRNA delivery designed to treat fibrosis, a complex disease characterized by increased oxidative stress, inflammation, and an excessive accumulation of extracellular matrices mainly consisting of collagen. Notably, […]
-
Data on PDX-001 Published in Advanced Functional Materials (IF 11.8)
4/15/2015
March 24, 2015
PDX Pharmaceutical, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, co-authored a paper published in the Advanced Functional Materials Journal that describes the novel nanoparticle siRNA delivery platform and its utility for targeting HER2-positive breast cancer. Approximately 15-25% of diagnosed breast cancers are classified as HER2-positive. HER2-positive breast […] -
President Invited to speak at the 4th International Conference on Nanotek & Expo.
4/15/2015
December 2, 2014
DoubleTree by Hilton Hotel San Francisco Airport, CA, USA.
Dr. Wassana Yantasee was invited to take part in the 2014 OMICS Group sponsored International Conference on Nanotek & Expo in San Francisco, CA. The talk “Bioreducible cross-linked polymer coated mesoporous silica nanoparticles for targeted delivery of siRNA and chemotherapeutics to HER2+ breast cancer” will […] -
President has served as a reviewer for the IMST-13 SBIR Bioengineering study section for the NIH
3/12/2015
PDX Pharma’s President has served as a reviewer for the IMST-13 Small Business SBIR Bioengineering study section for the National Institute of Heath (NIH) held on March 12th, 2015.
-
PDX Pharmaceuticals to Present at the RNA Nanotechnology Gordon Research Conference.
1/30/2015
February 1-6, 2015
Four Points Sheraton/Holiday Inn Express, Ventura, CA, USA.
Dr. Wassana Yantasee, President, PDX Pharmaceuticals, will participate in the RNA Technology: Converging Disciplines for the Advancement of Inter-RNA Interactions Gordon Research Conference. The poster titled “siRNA-nanoparticles for treating drug-resistant breast cancer” will provide an update to current efforts in developing PDX-001. -
$1.0M SBIR Contract Awarded by NCI
6/20/2014
Today, PDX Pharmaceuticals was awarded a phase II SBIR contract from National Cancer Institute for $1.0 million for the performance period of June, 2014-2016. The contract covers the development of siRNA-nanoparticle platform for HER2 positive breast cancer therapy. This award follows the success of Phase I contract of $200,000 from NCI to PDX Pharmaceuticals from September 2013-June 2014.
-
New team members
6/20/2014
Yantasee lab at OHSU welcome three new research assistants, Moataz Reda, Sam Mihelic, and Brandon Beckman. All graduated at the top of their class from Washington State University, Oregon State University, and University of Oregon, respectively.
-
Angel fund supports research
5/1/2014
Yantasee lab at OHSU was granted $1.4 million of angel fund to continue the development of nanoparticle platform for siRNA delivery for breast cancer therapies. This follows the angel fund of $750,000 for the initial phase studies.
-
President recognized
4/17/2014
Wassana Yantasee, PDX Pharmaceuticals’ President was featured in the article “Alumna Wassana Yantasee, Ph.D., Exemplifies Versatility of Oregon State’s MBA Program”.
-
2014 Oregon State Award
2/21/2014
Wassana Yantasee, the PDX Pharmaceuticals’ President was inducted into the Council of Outstanding Early Career Engineers, 2014 Oregon Stater Award.
RECENT PRESENTATIONS ON OUR TECHNOLOGY
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.